RXMD
As both oscillators and trend indicators click into "Buy Signal" territory, company has a very well-framed narrative coming into place that deserves a closer look:
Key Points:
• RXMD is on point as a leading speculative play on concerns around the future of the healthcare sector for all involved stakeholders
• RXMD is making real money, with trailing revs already coming in at $22.8M.
• RXMD is starting to see major topline growth, with quarterly y/y revs increasing at 37%.
• RXMD is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
• RXMD just recorded a MACD Bullish divergence and reversal, suggesting a technical change in trend back to the upside off a very important technical support level.
RXMD has a strong technical case as a current speculative play for market participants based on our analysis. In addition, the company sits at the crossroads of one of the most contentious issues of our time, and it’s making it work, with huge revenue growth and strong performance that is quantitatively improving on even a monthly basis.
With its new cannabinoid segment, the company is also a firm new entity in the explosive Hemp and CBD marketplace, where recent projections suggest explosive growth of as much as 125% CAGR looking out the next half-decade.
Thematically, technically, and fundamentally, RXMD has the numbers and the story to make a major splash from current levels,